Department of Inflammation and Immunity
Vincent K. Tuohy, Ph.D.
Staff
The Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research
Lerner Research Institute
9500 Euclid Avenue
Cleveland, Ohio 44195
Location:NB3-76
tuohyv@ccf.org
Phone: (216) 445-9684
Fax: (216) 444-8372
I have a long history of developing autoimmune mouse models for human diseases including multiple sclerosis, dilated cardiomyopathy, autoimmune inner ear disease, ovarian failure, interstitial cystitis, prostatitis, and breast failure. My research has focused on understanding the autoimmune mechanisms involved in tissue-specific destruction (e.g., “epitope spreading”) and on developing novel strategies for preventing disease progression. My current research activities focus on the preclinical and clinical development of vaccines designed not only to treat adult onset cancers but also to prevent such diseases with a focus on prevention of: 1) triple-negative breast cancer, the most lethal form of breast cancer and the most common form of this disease occurring in women at high genetic risk, and 2) epithelial ovarian cancer, the most lethal of all gynecologic malignancies. My prototypic strategy is based on the“retired self-protein hypothesis” whereby tissue-specific proteins that are no longer expressed in normal tissues as a result of the natural aging process may substitute for unavailable pathogens in targeting safe and effective prophylactic vaccination against emerging tumors expressing the targeted “retired” protein. Thus, I have extensive experience in targeting, modulating, and evaluating the immune response against autoantigens and harnessing the full biologic strength of autoimmunity to prevent and treat adult onset cancers like breast cancer and ovarian cancer.
In other words ...
Current Program:
- Cancer Vaccines
- Primary Immunoprevention of Adult Onset Cancers
- Breast Cancer
- Ovarian Cancer
- Cancer Immunotherapy
- Suparna Mazumder, Ph.D., Project Scientist
- Justin M. Johnson, B.S., Senior Research Technologist, Graduate Student, and Ph.D. Candidate
- Valerie Swank, B.S., Research Technologist
- Robert Aguilar, Ph.D., Visiting Scientist
- G. Thomas Budd, M.D., Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
- Alberto Montero, M.D. Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
- Peter Rose, M.D., Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
- Haider Mahdi, M.D., Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
- Erinn Downs-Kelly, D.O., Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH
- Jennifer Ko, M.D.,Ph.D., Central Biorepository, Cleveland Clinic, Cleveland, OH
- Sathyamangla V. Naga Prasad, Ph.D., Lerner Research Institute, Cleveland Clinic, Cleveland, OH
- Denise C. Connolly, Ph.D., Developmental Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA
Justin M. Johnson
Principal Research Technologist
Location:NN1-15
Phone:(216) 444-0613
johnsoj1@ccf.org
Fax:(216) 444-8372
Valerie Ann Swank
Sr. Research Technologist
Location:NN1-15
Phone:(216) 444-0613
swankv@ccf.org
Fax:(216) 444-8372
Selected Key References
Mazumder S, Johnson JM, Swank V, Dvorina N, Martelli E, Ko J, Tuohy VK. Primary Immunoprevention of epithelial ovarian carcinoma by vaccination against the extracellular domain of anti-Müllerian hormone receptor II. Cancer Prevention Research (Phila) 2017; 10:612-624
- Commentary: Shoemaker RH, Forsthuber TG. Targeting "Retired Antigens" for Cancer Immunoprevention. Cancer Prevention Research (Phila) 2017; 10:607-608.
- Commentary: Elia Ben-Ari, Experimental Ovarian Cancer Vaccine Shows Promise in Mice. Cancer Currents Blog Friday, November 17, 2017
Aguilar R, Johnson JM, Barrett P, Tuohy VK. Vaccination with inhibin-α provides effective immunotherapy against testicular stromal cell tumors. Journal for Immunotherapy of Cancer 2017; 5:37
Tuohy VK, Jaini R, Johnson JM, Loya MG, Wilk D, Downs-Kelly E, Mazumder S. Targeted vaccination against human α-lactalbumin for immunotherapy and primary immunoprevention of triple negative breast cancer. Cancers (Basel). 2016; 8(6). pii: E56
Tuohy VK. Primary immunoprevention: The great unmet need for controlling breast cancer. Oncology (Williston Park) 2016; 30(5):pii: 217055
Sakalar C, Mazumder S, Johnson JM, Altuntas CZ, Jaini R, Aguilar R, Naga Prasad SV, Connolly DC, Tuohy VK. Regulation of murine ovarian epithelial carcinoma by vaccination against the cytoplasmic domain of anti-Müllerian hormone receptor II. Journal of Immunology Research 2015; 2015:630287
Emens LA, Tuohy VK, Stanton SE, Clarke E. Immunotherapy for breast cancer: is it feasible? Immunotherapy 2015; 7:1135-1143
Jaini R, Altuntas CZ, Loya MG, Tuohy VK. Disruption of estrous cycle homeostasis in mice with experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 2015; 279:71-74
Tuohy VK. Bench-to-bedside challenges in developing immune protection against breast cancer. Cleveland Clinic Journal of Medicine 2014; 81:605-607
Bicer F, Altuntas CZ, Izgi K, Ozer A, Kavran M, Tuohy VK, Daneshgari F. Chronic pelvic allodynia is mediated by CCL2 through mast cells in an experimental autoimmune cystitis model. American Journal of Physiology: Renal Physiology 2015; 308:F103-113
Tuohy VK. Retired self-proteins as vaccine targets for primary immunoprevention of adult-onset cancers. Expert Review of Vaccines 2014; 13:1447-1462
Jaini R, Rayman P, Cohen PA, Finke JH, Tuohy VK. Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires carefulscheduling to achieve productive immunotherapy. International Journal of Cancer 2014; 134:1695-1705
Izgi K, Altuntas CZ, Bicer F, Ozer A, Sakalar C, Li X, Tuohy VK, Daneshgari F. Uroplakin peptide-specific autoimmunity initiates interstitial cystitis/painful bladder syndrome in mice. PLoS One 2013; 8:e72067
Jaini R, Popescu DC, Flask CA, Macklin WB, Tuohy VK. Myelin antigen load influences antigen presentation and severity of central nervous system autoimmunity. Journal of Neuroimmunology 2013; 259:37-46
Altuntas CZ, Daneshgari F, Veizi E, Izgi K, Bicer F, Ozer A, Grimberg KO, Bakhautdin B, Sakalar C, Tasdemir C, Tuohy VK. A novel murine model of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) induced by immunization with a spermine binding protein (p25) peptide. American Journal of Physiology: Regulation, Integrative, and Comparative Physiology 2013; 304:R415-422
Altuntas CZ, Daneshgari F, Izgi K, Bicer F, Ozer A, Sakalar C, Grimberg KO, Sayin I, Tuohy VK. Connective tissue and its growth factor CTGF distinguish the morphometric and molecular remodeling of the bladder in a model of neurogenic bladder. American Journal of Physiology: Renal Physiology 2012; 303:F1363-1369
Kesaraju P, Jaini R, Johnson JM, Altuntas CZ, Gruden JJ, Sakalar C, Tuohy VK. Experimental autoimmune breast failure: a model for lactation insufficiency, postnatal nutritional deprivation, and prophylactic breast cancer vaccination. American Journal of Pathology 2012; 181:775-784
Altuntas CZ, Daneshgari F, Sakalar C, Goksoy E, Gulen MF, Kavran M, Qin J, Li X, Tuohy VK. Autoimmunity to uroplakin II causes cystitis in mice: a novel model of interstitial cystitis. European Urology 2012; 61:193-200
Altuntas CZ, Jaini R, Kesaraju P, Jane-wit D, Johnson JM, Covey K, Flask CA, Dutertre M, Picard JY, Tuohy VK. Autoimmune mediated regulation of ovarian tumor growth. Gynecologic Oncology 2012; 124:98-104
Altuntas CZ, Daneshgari F, Sakalar C, Goksoy E, Gulen MF, Kavran M, Qin J, Li X, Tuohy VK. Autoimmunity to uroplakin II causes cystitis in mice: a novel model of interstitial cystitis. European Urology 2012; 61:193-200
Tuohy VK, Jaini R. Prophylactic cancer vaccination by targeting functional non-self. Annals of Medicine 2011; 43:356-365
Tuohy VK. A prophylactic vaccine for breast cancer? Why not?Breast Cancer Research 2010; 12:405
Jaini R, Kesaraju P, Johnson JM, Altuntas CZ, Jane-Wit D, Tuohy VK. An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nature Medicine 2010; 16:799-803
- Commentary: Alexandra Flemming. Cancer: steps towards a prophylactic breast cancer vaccine. Nature Reviews Drug Discovery 2010; 9:594-595
- Commentary: Michael J. Haas. Breast cancer prophylaxis. Breast cancer prophylaxis. SciBX 2010; 3(24)
- Commentary: Michael Eisenstein. Vaccines: know your enemy. Nature 2011; 471:S8-9
- Commentary: Kelly Rae Chi. Cancer Research: Promise of protection. Nature 2011; 471:537-538
Kang Z, Altuntas CZ, Gulen MF, Liu C, Giltiay N, Qin H, Liu L, Qian W, Ransohoff RM, Bergmann C, Stohlman S, Tuohy VK, Li X. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity 2010; 32:414-425
Gulen MF, Kang Z, Bulek K, Youzhong W, Kim TW, Chen Y, Altuntas CZ, Sass Bak-Jensen K, McGeachy MJ, Do JS, Xiao H, Delgoffe GM, Min B, Powell JD, Tuohy VK, Cua DJ, Li X. The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity 2010; 32:54-66
Staschke KA, Dong S, Saha J, Zhao J, Brooks NA, Hepburn DL, Xia J, Gulen MF, Kang Z, Altuntas CZ, Tuohy VK, Gilmour R, Li X, Na S. IRAK4 kinase activity is required for Th17 differentiation and Th17-mediated disease. Journal of Immunology 2009; 183:568-577
Tigno-Aranjuez JT, Jaini R, Tuohy VK, Lehmann PV, Tary-Lehmann M. Encephalitogenicity of complete Freund's adjuvant relative to CpG is linked to induction of Th17 cells. Journal of Immunology 2009; 183:5654-5661
Buniel MC, Geelan-Hansen K, Weber PC, Tuohy VK. Immunosuppressive therapy for autoimmune inner ear disease. Immunotherapy 2009; 1:425-434
No news currently found.